GlassScriptPhysician profile
David R Silvers
NPI 1316052087
$92,385.57
in general payments reported to CMS, 2019-2025
40 companies · $19K in 2025
The $19K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,726 · 2020: $8,404 · 2021: $9,161 · 2022: $21K · 2023: $21K · 2024: $6,113 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $7,009 · Travel and Lodging: $5,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,747.92 |
| Food and Beverage | $7,009.02 |
| Travel and Lodging | $5,319.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66,704.24 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Exact Sciences Corporation | $17,117.29 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,906.43 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,209.27 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $936.86 | 2019-2025 | Entyvio |
| Celgene Corporation | $771.21 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $746.51 | 2019-2025 | |
| Pfizer INC. | $602.33 | 2019-2025 | |
| Genzyme Corporation | $280.66 | 2023-2025 | |
| Allergan, INC. | $185.09 | 2019 | |
| Redhill Biopharma INC. | $179.70 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $171.39 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $169.50 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $111.71 | 2019-2020 | |
| Braintree Laboratories, INC. | $108.54 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Silvers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.